Clinical Outcomes Solutions
New AI-Driven Platform to Transform Clinical Outcomes Assessment: COA-AI Software Merges AI Efficiency with Researcher Expertise
TUCSON, AZ / ACCESSWIRE / December 15, 2023 / Clinical Outcomes Solutions (COS), a leading clinical research consulting group, in collaboration with BioSpark AI Technologies Inc., today announced the launch of COA-AI, a pioneering software company aimed at revolutionizing Clinical Outcomes Assessment (COA) with the aid of Artificial Intelligence (AI).
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
COA-AI emerges as a groundbreaking tool in the development of conceptual models, identification of outcome measures, conduction of measurement gap analyses, and synthesis of published COA evidence, marking a significant milestone in the field of clinical outcomes research.
Stacie Hudgens, CEO of Clinical Outcomes Solutions, emphasized the importance of the launch, stating, "The launch of this software is quite timely for the field of COA as it ensures that we can provide accurate and timely COA desk research to support life science companies with a patient-focused strategy for their clinical development programs. This software will allow for the synthesis and presentation of published information in an expedited manner while retaining the touch of an experienced researcher."
Kristian Thorlund, CEO of BioSpark AI Technologies Inc., highlighted the transformative potential of the software: "Large language models have taken the world by storm, Clinical Outcomes Assessment is next. The COA-AI software is a perfect fusion of human touch and AI innovation. The software's AI models replicate key components of the robust workflow and research infrastructure that the team at Clinical Outcomes Solutions has spent so many years perfecting. It is almost perplexing to think about how much time this will save COA researchers in the future."
Tara Symonds, CSO of Clinical Outcomes Solutions, sheds light on the practical impact of COA-AI: "This new COA-AI system, designed to bring together the use of AI and researcher insight, will help expedite our ability to quickly develop robust conceptual models to enable dialogue with clients about their COA endpoint strategy, and then based on this, help quickly decide on best COA measures. This will provide clients, often time-constrained, with a rapid solution to deciding which COA measures to include in forthcoming clinical trials."
The partnership between Clinical Outcomes Solutions and BioSpark AI Technologies Inc. reflects a shared commitment to enhancing patient care through technological advancements. COA-AI is set to redefine the landscape of clinical outcomes research, promising efficiency and precision in a field where time and accuracy are of the essence.
For more information about COA-AI and its impact on clinical outcomes research, please contact Clinical Outcomes Solutions at info@clinoutsolutions.com
About Clinical Outcomes Solutions:
Established in 2013, Clinical Outcomes Solutions is a leader in the field of COA, offering comprehensive services, strategies, and solutions across all facets of clinical outcomes research to assist with data-driven decisions for informing patient care. For more information about Clinical Outcome Solutions, visit www.clinoutsolutions.com.
About BioSpark AI Technologies Inc.:
Founded in 2022, BioSpark is a rapidly growing artificial intelligence (AI) start-up on a mission to dramatically accelerate the speed of delivery of high-quality medical research. Powered by proprietary technologies to streamline and minimize the need for manual curation, BioSpark is able to deliver high-quality, complete longitudinal COA data at unparalleled speeds. For more information, visit www.biospark.ai
Contact Information
Stacie Hudgens
Chief Executive Officer
stacie.hudgens@clinoutsolutions.com
(520) 325-9510
Sean Forrest
Senior Marketing Manager
sean.forrest@clinoutsolutions.com
(847) 530-8152
Related Images
View the original press release on newswire.com.
SOURCE: Clinical Outcomes Solutions
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference9.1.2026 18:35:00 CET | Press release
MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level). About PromiCell, Inc. PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 T
Datavault AI Expands IBM Collaboration to Deploy Enterprise-Grade AI at the Edge with Available Infrastructure's SanQtum AI Platform8.1.2026 13:00:00 CET | Press release
Datavault AI will activate a secured multi-city edge AI network for real-time data tokenization, security, and monetization across New York and Philadelphia NEW YORK, NY / ACCESS Newswire / January 8, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in instant data monetization & enterprise digital twins, announced it will deliver enterprise-grade AI performance at the edge in New York and Philadelphia through an expanded collaboration with IBM using the SanQtum AI platform. Operated by Available Infrastructure, SanQtum AI is a fleet of synchronized micro edge data centers running IBM's watsonx portfolio of AI products on a zero-trust network. The combined deployment is designed to enable cybersecure data storage and compute, real-time data scoring, tokenization, and ultra-low-latency, across two of the most data-dense metro regions in the United States. By running Datavault AI's Information Data Exchange and DataScore agents - built with watsonx - within SanQtum AI's zero-trust edge e
Ascend Advanced Therapies - ABL Inc. Further Strengthens Executive Team as It Drives Forward an Ambitious Growth Strategy8.1.2026 13:00:00 CET | Press release
Seiga Ohmine to join as Chief Commercial Officer, Sharad Dubey as Chief Financial Officer and Patrick Lansky as Senior Vice President of Global Business Development Appointments underscore Ascend-ABL's commitment to scientific rigor, operational excellence, and strategic growth ROCKVILLE, MARYLAND / ACCESS Newswire / January 8, 2026 / Ascend Advanced Therapies - ABL Inc. today announced significant appointments to its leadership team. Seiga Ohmine Ph.D. joins as Chief Commercial Officer (CCO) Sharad Dubey CA, CPA joins as Chief Financial Officer (CFO) Patrick Lansky joins as Senior Vice President of Global Business Development These appointments reflect Ascend-ABL's focus on strengthening scientific leadership, operational discipline, and customer-centric execution as the company sharpens its positioning as a trusted CDMO partner for advanced viral modalities. Commenting on the appointments, Alessandra Rispoli, Chief Executive Officer of Ascend-ABL said, "We are making strong progress
Market Logic Announces Technology Partnership with Zappi to Accelerate Innovation with AI8.1.2026 08:00:00 CET | Press release
BERLIN, DE / ACCESS Newswire / January 8, 2026 / Market Logic Software is excited to announce a technology partnership with Zappi designed to help leading brands develop, refine, and test new product concepts faster than ever before. United by a joint agentic AI framework, this collaboration brings together advanced AI capabilities from both companies, marking a pivotal shift in how organizations execute insights-driven innovation. Through AI-to-AI integrations, linking two powerful AI platforms, enterprises can now enrich their product innovation process with a comprehensive data ecosystem. Specially trained DeepSights AI agents within Market Logic's Innovation Studio continuously monitor, analyse, and synthesize market research, news, and operational data-allowing for accelerated concept generation and more informed decision-making. With just a couple of clicks, customers can seamlessly progress to testing their concepts with real people, thanks to Zappi's real-world respondent solut
RE Royalties Announces up to a USD $9.0 Million Portfolio-Level Royalty Investment with Solaris Energy Inc.7.1.2026 22:20:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / January 7, 2026 / RE Royalties Ltd. (TSXV:RE)(OTCQX:RROYF) ("RE Royalties" or the "Company") is pleased to announce that it has entered into a definitive agreement with Solaris Energy Inc. ("Solaris") to invest up to USD $9.0 million to acquire a royalty interest (the "Royalty Purchase") in two portfolios of distributed generation ("DG") solar projects located throughout the United States. The first portfolio consists of 15 projects including 9 under construction with several nearing operation, and 6 in development, located across California, Maine, Delaware, New Hampshire and Colorado ("Portfolio 1"). The second portfolio comprises 9 more projects, the final composition of which may evolve as the projects advance ("Portfolio 2"). The transaction represents the acquisition of a portfolio level royalty on a diversified portfolio of DG solar assets and marks the exciting beginning of a new partnership between the two parties. The Royalty Purchase for Por
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom